In its 2023 financial year, Novo Nordisk reported a significant increase in net profit, rising to 83.68 billion Danish kroner from the previous year's 55.52 billion. Earnings per share similarly increased, reaching 18.62 Danish kroner compared to the previous year's 12.22 Danish kroner. Operating profit saw a rise of 37% in Danish kroner and by 44% at constant exchange rates, amounting to 102.6 billion kroner.
Net sales for the 2023 fiscal year also saw a considerable boost, rising to 232.26 billion Danish kroner from 176.96 billion the previous year. These sales figures demonstrated an increase of 31% in Danish kroner and 36% at constant exchange rates.
The fourth quarter of the fiscal year experienced a 62% growth in net profit, reaching 21.96 billion kroner. Earnings per share also grew by 63%, amounting to 4.91 kroner, and net sales came in at 65.86 billion kroner, compared to the previous year’s 48.09 billion.
For the 2024 fiscal year, Novo Nordisk has forecasted operating profit growth to be between 21% and 29% at constant exchange rates. Sales growth is anticipated to range between 18% and 26% at the same rates.
The company’s board plans to propose a final dividend of 6.40 kroner per share for 2023 at the Annual General Meeting. Therefore, the projected total dividend for 2023 is expected to be 9.40 kroner per share. Additionally, the board has approved the initiation of a new share repurchase program, worth up to 20 billion kroner.
